Ceribell, Inc. (CBLL) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The study “EEG Abnormalities in Adult ICU Patients With High Risk of Delirium” aims to measure how often brain wave changes appear in very sick adults at high risk of delirium. It focuses on simple, bedside brain monitoring and could shape how hospitals manage delirium, a costly and common ICU problem.
The main intervention is the Ceribell EEG System, a compact brain monitoring device. It is designed to give quick EEG readings at the bedside, helping staff spot brain dysfunction that might be missed otherwise.
The trial is observational and prospective, meaning doctors will watch what happens over time without changing standard care. All enrolled patients receive device monitoring, so there is no random assignment or blinding, and the main goal is to describe patterns rather than test a drug.
The study was first submitted on March 5, 2026, and is listed as not yet recruiting, signaling that site setup is still underway. The last update was filed on April 13, 2026, which confirms the plan is active and provides a fresh marker for investors tracking execution risk.
For investors, this update supports Ceribell’s push to expand EEG use beyond seizure detection into delirium management, a large and under-served market. Positive real-world data could strengthen CBLL’s hospital sales pitch and valuation, while rivals in ICU monitoring and EEG must watch how fast point of care brain tools gain traction.
The study is currently in preparation and recently updated, with further details available on the ClinicalTrials portal.